Takeda Pharmaceutical Stock Forecast, Price & News

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Takeda Pharmaceutical in the last twelve months. There are currently 2 hold ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" Takeda Pharmaceutical stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in TAK, but not buy additional shares or sell existing shares.
View analyst ratings for Takeda Pharmaceutical or view top-rated stocks.

Wall Street analysts have given Takeda Pharmaceutical a "Hold" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Takeda Pharmaceutical wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Takeda Pharmaceutical saw a increase in short interest during the month of August. As of August 31st, there was short interest totaling 5,810,000 shares, an increase of 28.3% from the August 15th total of 4,530,000 shares. Based on an average trading volume of 1,790,000 shares, the short-interest ratio is currently 3.2 days. Currently, 0.2% of the shares of the company are sold short.
View Takeda Pharmaceutical's Short Interest.

Takeda Pharmaceutical is scheduled to release its next quarterly earnings announcement on Thursday, November 4th 2021.
View our earnings forecast for Takeda Pharmaceutical.

Takeda Pharmaceutical Company Limited (NYSE:TAK) released its earnings results on Friday, July, 30th. The company reported $0.51 EPS for the quarter. The business earned $8.68 billion during the quarter. Takeda Pharmaceutical had a net margin of 14.69% and a trailing twelve-month return on equity of 13.00%.
View Takeda Pharmaceutical's earnings history.

Takeda Pharmaceutical's stock was trading at $17.15 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, TAK shares have decreased by 0.9% and is now trading at $17.00.
View which stocks have been most impacted by COVID-19.

Takeda Pharmaceutical pays an annual dividend of $0.68 per share and currently has a dividend yield of 3.95%. The dividend payout ratio of Takeda Pharmaceutical is 34.34%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, Takeda Pharmaceutical will have a dividend payout ratio of 72.34% next year. This indicates that Takeda Pharmaceutical will be able to sustain or increase its dividend.
View Takeda Pharmaceutical's dividend history.

Takeda Pharmaceutical updated its FY 2021 earnings guidance on Friday, August, 6th. The company provided earnings per share (EPS) guidance of $3.590-$3.590 for the period. The company issued revenue guidance of $30.67 billion-$30.67 billion.

Some companies that are related to Takeda Pharmaceutical include AbbVie (ABBV), Novartis (NVS), Merck & Co., Inc. (MRK), AstraZeneca (AZN), Bristol-Myers Squibb (BMY), Sanofi (SNY), GlaxoSmithKline (GSK), CSL (CSLLY), Zoetis (ZTS), Regeneron Pharmaceuticals (REGN), Bayer Aktiengesellschaft (BAYRY), Vertex Pharmaceuticals (VRTX), BeiGene (BGNE), Astellas Pharma (ALPMY) and MERCK Kommanditgesellschaft auf Aktien (MKGAF).
View all of TAK's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Takeda Pharmaceutical investors own include Cisco Systems (CSCO), Johnson & Johnson (JNJ), Alibaba Group (BABA), Pfizer (PFE), Verizon Communications (VZ), AbbVie (ABBV), CVS Health (CVS), Gilead Sciences (GILD), AT&T (T) and Abbott Laboratories (ABT).

Takeda Pharmaceutical trades on the New York Stock Exchange (NYSE) under the ticker symbol "TAK."

Takeda Pharmaceutical's stock is owned by a number of retail and institutional investors. Top institutional investors include ARK Investment Management LLC (0.49%), Price T Rowe Associates Inc. MD (0.17%), Macquarie Group Ltd. (0.15%), Northern Trust Corp (0.13%), Parametric Portfolio Associates LLC (0.12%) and Mondrian Investment Partners LTD (0.12%).

TAK stock was sold by a variety of institutional investors in the last quarter, including ARK Investment Management LLC, GMT Capital Corp, Susquehanna International Group LLP, Renaissance Technologies LLC, Capula Management Ltd, Bank of America Corp DE, Northern Trust Corp, and First Trust Advisors LP.

TAK stock was bought by a variety of institutional investors in the last quarter, including Point72 Asset Management L.P., Polygon Management Ltd., LMR Partners LLP, Macquarie Group Ltd., Oasis Management Co Ltd., HAP Trading LLC, Manning & Napier Group LLC, and Brandes Investment Partners LP.

Shares of TAK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of TAK stock can currently be purchased for approximately $17.00.

Takeda Pharmaceutical has a market capitalization of $53.80 billion and generates $30.17 billion in revenue each year. The company earns $3.53 billion in net income (profit) each year or $1.98 on an earnings per share basis.

Takeda Pharmaceutical employs 2,021 workers across the globe.

The following companies are subsidiares of Takeda Pharmaceutical: ARIAD Pharmaceuticals, Baxalta Manufacturing S.à r.l., IDM Pharma Inc., Intellikine, Inviragen, LigoCyte Pharmaceuticals, Meritage Pharma Inc., Millennium Pharmaceuticals, Millennium Pharmaceuticals Inc., Nihon Pharmaceutical Co. Ltd., Nycomed Pharma, PvP Biologics, Shire, Shire ViroPharma LLC, Takeda (China) Holdings Co. Ltd., Takeda AS, Takeda Austria GmbH, Takeda Bio Development Center, Takeda California Inc., Takeda Consumer Healthcare Company Limited, Takeda Development Center Americas Inc., Takeda Development Center Asia Pte. Ltd., Takeda Development Centre Europe Ltd., Takeda Distribuidora Ltda., Takeda France S.A.S., Takeda GmbH, Takeda Ireland Limited, Takeda Italia S.p.A., Takeda Pharma A/S, Takeda Pharmaceutical (China) Company Limited, Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals Korea Co. Ltd., Takeda Pharmaceuticals Limited Liability Company, Takeda Pharmaceuticals U.S.A. Inc., Takeda UK Limited, Takeda Vaccines Inc., Takeda Vaccines Pte. Ltd., and TiGenix.

Takeda Pharmaceutical was founded in 1781.

The official website for Takeda Pharmaceutical is www.takeda.com.

Takeda Pharmaceutical is headquartered at 1-1 NIHONBASHI-HONCHO 2-CHOME CHUO-KU, TOKYO M0, 103-8668.

Takeda Pharmaceutical's mailing address is 1-1 NIHONBASHI-HONCHO 2-CHOME CHUO-KU, TOKYO M0, 103-8668. The company can be reached via phone at (166) 204-2111.